283
Participants
Start Date
November 11, 2024
Primary Completion Date
May 31, 2027
Study Completion Date
May 31, 2027
Daplusiran/Tomligisiran Dose Level 1
Daplusiran/Tomligisiran dose level 1 will be administered
Daplusiran/Tomligisiran Dose Level 2
Daplusiran/Tomligisiran dose level 2 will be administered
Bepirovirsen
Bepirovirsen will be administered
Placebo
Placebo will be administered
GSK Investigational Site, Tau-Yuan
GSK Investigational Site, Taichung
GSK Investigational Site, Kaohsiung City
GSK Investigational Site, Kaohsiung City
GSK Investigational Site, Brussels
GSK Investigational Site, Auckland
GSK Investigational Site, Reiger Park
GSK Investigational Site, Papatoetoe Auckland
GSK Investigational Site, Westmead
GSK Investigational Site, Johannesburg
GSK Investigational Site, Edegem
GSK Investigational Site, Fitzroy
GSK Investigational Site, Ghent
GSK Investigational Site, New York
GSK Investigational Site, Berlin
GSK Investigational Site, Athens
GSK Investigational Site, Berlin
GSK Investigational Site, Athens
GSK Investigational Site, Marseille
GSK Investigational Site, Ansan
GSK Investigational Site, Philadelphia
GSK Investigational Site, León
GSK Investigational Site, Bergamo
GSK Investigational Site, Madrid
GSK Investigational Site, Hanover
GSK Investigational Site, Toulouse
GSK Investigational Site, Padua
GSK Investigational Site, Salamanca
GSK Investigational Site, Santander
GSK Investigational Site, Valencia
GSK Investigational Site, Busan
GSK Investigational Site, Münster
GSK Investigational Site, Pusan
GSK Investigational Site, Florence
GSK Investigational Site, Minneapolis
GSK Investigational Site, Pisa
GSK Investigational Site, Lyon
GSK Investigational Site, Napoli
GSK Investigational Site, Limoges
GSK Investigational Site, Clichy
GSK Investigational Site, Créteil
GSK Investigational Site, San Francisco
GSK Investigational Site, San Jose
GSK Investigational Site, Beijing
GSK Investigational Site, Singapore
GSK Investigational Site, Singapore
GSK Investigational Site, Shanghai
GSK Investigational Site, Guangzhou
GSK Investigational Site, Chengdu
GSK Investigational Site, Aracaju
GSK Investigational Site, Curitiba
GSK Investigational Site, Manaus
GSK Investigational Site, São Paulo
GSK Investigational Site, Calgary
GSK Investigational Site, Ottawa
GSK Investigational Site, Toronto
GSK Investigational Site, Montreal
GSK Investigational Site, Pokfulam
GSK Investigational Site, Shatin
GSK Investigational Site, Milan
GSK Investigational Site, Roma
GSK Investigational Site, Chiba
GSK Investigational Site, Hokkaido
GSK Investigational Site, Hokkaido
GSK Investigational Site, Hyōgo
GSK Investigational Site, Kagawa
GSK Investigational Site, Kagawa
GSK Investigational Site, Kumamoto
GSK Investigational Site, Kumamoto
GSK Investigational Site, Osaka
GSK Investigational Site, Osaka
GSK Investigational Site, Tokyo
GSK Investigational Site, Yamanashi
GSK Investigational Site, Seoul
GSK Investigational Site, Seoul
GSK Investigational Site, Barcelona
GSK Investigational Site, Barcelona
GSK Investigational Site, London
GSK Investigational Site, London
GSK Investigational Site, London
GSK Investigational Site, Middlesbrough
Lead Sponsor
GlaxoSmithKline
INDUSTRY